{"entity":{"id":"nct04384484","kind":"trial","name":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym","aka":["LOTIS-5"],"tldr":"A phase 3 trial of Loncastuximab tesirine, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by ADC Therapeutics S.A., active and no longer recruiting.","summary":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma is a phase 3 interventional study registered as NCT04384484 by ADC Therapeutics S.A., with 440 participants enrolled, started 2020-09-16 and due to reach its primary completion in 2026-03-31. Interventions recorded: Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin. Conditions listed: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04384484","url":"https://clinicaltrials.gov/study/NCT04384484"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["adc","monoclonal-antibody"],"targets":[],"drugs":["zynlonta","rituximab","gemcitabine","capox"],"companies":["adc-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04384484","phase":"3","setting":"A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)","sponsor":"ADC Therapeutics S.A.","participation":[{"nct":"NCT04384484","source":"https://clinicaltrials.gov/study/NCT04384484","fetchedAt":"2026-10-07T16:53:19.341Z","studySha256":"c2d90dd376c0ec0a7a696c4d24bbf1c8b259342f49ad83876fcadcead623848a","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-04-28","leadSponsor":"ADC Therapeutics S.A.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":440,"enrolmentType":"ACTUAL","siteCount":144,"recruitingSiteCount":0,"countries":["Argentina","Belgium","Brazil","Canada","Chile","China","Czechia","France","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Poland","Puerto Rico","Spain","Switzerland","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2020-09-16","startedType":"actual","enrolled":440,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04384484/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"adc-therapeutics","kind":"company","name":"ADC Therapeutics","route":"/companies/adc-therapeutics/"}]}}